Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 2:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Umbilical Cord Lining Stem Cells Clear all
Terminated Phase 1 Interventional

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

NCT00376519
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Secondary Myelofibrosis
Interventions
cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, Treg cell infusion, umbilical cord blood transplantation, total-body irradiation
Drug · Procedure · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 28, 2026, 2:13 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Stem Cell Transplantation for Hematological Malignancies

NCT00176839
View directory record Official record
Conditions
Leukemia, Lymphocytic, Acute, AML, MDS
Interventions
Stem Cell Transplant, Busulfan, Cyclophosphamide, Melphalan, G-CSF, ATG
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 35 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 28, 2026, 2:13 AM EDT
Completed Phase 1 Interventional

PHASE 1, OPEN-LABEL SAFETY STUDY OF UMBILICAL CORD LINING MESENCHYMAL STEM CELLS (CORLICYTE®) TO HEAL CHRONIC DIABETIC FOOT ULCERS

NCT04104451
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Corlicyte
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 28, 2024 · Synced Sep 28, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

Stem Cell Transplantation for Hurler

NCT00176917
View directory record Official record
Conditions
Mucopolysaccharidosis I, Mucopolysaccharidosis VI, Mannosidosis, Mucolipidosis Type II (I-cell Disease)
Interventions
Stem Cell Transplant, Busulfan, Cyclophosphamide, ATG
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 28, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

NCT00357565
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Childhood Acute Myeloid Leukemia in Remission, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Previously Treated Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess Blasts, Refractory Anemia, De Novo Myelodysplastic Syndrome, Childhood Myelodysplastic Syndrome
Interventions
filgrastim, busulfan, cyclosporine, fludarabine phosphate, melphalan, mycophenolate mofetil, umbilical cord blood transplantation
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 3 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 28, 2026, 2:13 AM EDT
Completed Early Phase 1 Interventional

u-STOP LVAD Bleed: Utilization of Umbilical Cord Lining Stem Cells (ULSCs) To Prevent Left Ventricular Assist Device (LVAD) Associated Angiodysplastic Bleeding

NCT04811261
View directory record Official record
Conditions
Angiodysplastic Bleeding
Interventions
Intravenous Infusion of UCLSCs
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Sep 28, 2026, 2:13 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Stem Cell Transplant for Inborn Errors of Metabolism

NCT00176904
View directory record Official record
Conditions
Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Gaucher's Disease, Fucosidosis, Wolman Disease, Niemann-Pick Disease, Batten Disease, GM1 Gangliosidosis, Tay Sachs Disease, Sandhoff Disease
Interventions
Stem Cell Transplant, Busulfan, Cyclophosphamide, Antithymocyte Globulin
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 28, 2026, 2:13 AM EDT
Completed Early Phase 1 Interventional

Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)

NCT04723303
View directory record Official record
Conditions
Polymyositis, Dermatomyositis
Interventions
Umbilical Cord Lining Stem Cells
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 28, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

NCT00309842
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
filgrastim, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Sep 28, 2026, 2:13 AM EDT
Completed Phase 1Phase 2 Interventional

Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

NCT04494386
View directory record Official record
Conditions
Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS, Coronavirus
Interventions
Umbilical Cord Lining Stem Cells (ULSC), Placebo (carrier control)
Biological · Other
Lead sponsor
Restem, LLC.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Miami, Florida • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Sep 28, 2026, 2:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

NCT00801931
View directory record Official record
Conditions
Leukemia, Lymphoma, Neuroblastoma, Immunodeficiencies, Anemia
Interventions
Alemtuzumab, Total Body Irradiation, Melphalan, Busulfan, Phenytoin, Fludarabine, Cyclophosphamide, Horse Antithymocyte Globulin, Rabbit Antithymocyte Globulin, Thiotepa
Drug · Radiation
Lead sponsor
Columbia University
Other
Eligibility
Up to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 28, 2026, 2:13 AM EDT
Recruiting Phase 1 Interventional

Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT07086521
View directory record Official record
Conditions
FSHD - Facioscapulohumeral Muscular Dystrophy
Interventions
ULSC, Placebo
Biological
Lead sponsor
Restem, LLC.
Industry
Eligibility
15 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 28, 2026, 2:13 AM EDT
Recruiting Phase 2 Interventional

Personalized NK Cell Therapy in CBT

NCT02727803
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Myeloid Leukemia With Variant MLL Translocations, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Chemotherapy-Related Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Gene Mutation, Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
Interventions
Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Rituximab, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Biological · Drug · Other + 2 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 28, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke

NCT03004976
View directory record Official record
Conditions
Stroke, Stroke, Acute, Brain Injury, Acute
Interventions
Umbilical Cord Blood, Placebo
Biological · Other
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Aurora, Colorado • Gainesville, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Sep 28, 2026, 2:13 AM EDT
Recruiting Phase 2Phase 3 Interventional

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)

NCT07160205
View directory record Official record
Conditions
Idiopathic Inflammatory Myositis (IIM), DERMATOMYOSITIS OR POLYMYOSITIS
Interventions
ULSC (1.5 x 10^8 cells/dose), Placebo (no cells)
Biological
Lead sponsor
Restem, LLC.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Gainesville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 28, 2026, 2:13 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Enhancing Skin Rejuvenation Using Laser and Exosomes

NCT07281690
View directory record Official record
Conditions
Laser Therapy, Exosomes
Interventions
1064-nm Nd:YAG Laser Treatment, Topical Umbilical Cord-Derived Exosomes (UC-MSC Exosomes)
Device · Biological
Lead sponsor
Laser Beamer Skincare
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 28, 2026, 2:13 AM EDT
Terminated Phase 2 Interventional Results available

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

NCT00354172
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI)
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 28, 2026, 2:13 AM EDT